Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Understanding Hard to Treat Diseases(HTDS)
Htds is the holding company for a few small but very aggressive biotech/pharmaceutical companies. The key holding is mellow hope pharma of China. This is one of the largest exporters of biological vaccinations in China. The export to many countries in the pacific rim, South America, and Central America. They have many products including vaccines for hepatitis and HIV. The most compelling argument for this company however is that there are one of only two Chinese companies that have been approved by the government for an H1N1 vaccine(Swine Flu). The other subsidiary is Slavica Bio Chem which heads in the mind up cancer project. This company is aggressively seeking groundbreaking cancer solutions, multiple sclerosis research, and advances in treating massive brain trauma.Why To Invest...
1. Mellow Hope is one of only two approved companies in china that have received clearance by the government to produce and administer the H1N1 vaccine. The have a current large order from the Chinese government(20 million doses) and management has stated that in mid October they would be announcing possible contracts with several other countries.
2. Slavic Bio Chem has groundbreaking cancer research. Today the company announced that they are of the opinion that they have isolated the gene that specifically causes lung cancer. This could be one of the first indications to support the argument that many medical professional have. That cancer is present in everyones body, that somewhere there is a mechanism that triggers it. Isolating the gene that may cause a specific cancer gives tremendous insight on how that should be treated. Slavic Bio Chem is currently in talks with a larger Canadian Bio company as either a partner or a buyer to further their studies.
3. Continuing on number two this would benefit current shareholders in that management has decided that the sell would be distributed to current shareholders in the form of a dividend. If this does not happen the company is also considering spin offs and awarding current shareholders a stake in the new company as a stand alone.
4. The companies current market cap is about 30 million. If they were to reach a similar market cap of the only other approved H1N1 company in china, Sinovac, the company would trade at .05 to .06. This alone with no other stimulus is a 400% increase over current share price.
5. The company has faced many current obstacles that have depressed the share price. Pink sheets has put the company on "warning" or caveat emptor because the company has launched its own investigation into naked shorting of the stock. Pink sheets sees this as a negative because it gives the impression that all facts may not be present to investors. This is ludacris. Naked shorting is a part of the entire market, totally ignored by the SEC, and a few companies have to pay the price for protecting themselves. Why is this good? All the good news that has come out of late has caused no movement because of the "concern" with this company. Founded or not it is a deterrent.
THE NEXT VERMILLION ?Hard To Treat Diseases (HTDS) Exploration Of A 25 Billion Dollar Industry Regenerative Medicine and Stem Cell Bank Targeted Merger
Press Release
Source: Hard to Treat Diseases
On 11:30 am EST, Tuesday November 24, 2009
Buzz up! 0 Print
BELGRADE, Serbia, Nov. 24 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS; http://www.htdsmedical.com/) and its operating subsidiary Slavica Bio Chem, is providing this brief update to its followers and shareholders. HTDS management continues due diligence with the EU stem cell company and merger discussions. This relates to the previous announcement on or about Oct 29, 2009 which the company made. http://www.pinksheets.com/pink/quote/quote.jsp?symbol=HTDS#getNews.
HTDS and Slavica Biochem are also discussing on expanding the research topics to include other applications from the field of regenerative medicine. The newly discussed project would be dealing with a method for treatment of damaged articular cartilage - the autologous implantation of in vitro cultivated chondrocytes (the cells which form the cartilage). This new technique is one of the most important orthopaedic achievements of this century. As aforementioned the research team from Slavica BioChem http://www.slavicabiochem.com is considering a merger with the bio company from one of the EU countries where this technology is already being deployed. The HTDS management does not wish to disturb its current share structure in the merger discussions. One alternative solution currently being explored by the management is to license this technology and to use HTDS own cash resources and low labour costs in Serbia to launch both enterprises in Serbia. The company would generate revenues with the export throughout western Europe.
Marker Reports and similar research studies indicate that stem cell and regenerative medicine is a ~$25 billion dollar new industry. (2008 data) (source) Jain PharmaBiotech's "Cell Therapy" market report: (1) related to the commercialization of cell therapies, regenerative medicine products, (market, and commercial overview data.) http://www.docstoc.com/docs/1025099/Cell-Therapy-Business-Market-Summary-(July-2008) (unauthorized link)
A medical research report of the autologous chondrocytes project is filed with Pink Sheets http://www.pinksheets.com under the "Filings Tab".
HTDS operates two subsidiaries, Slavica Bio Chem Co and China Mellow Hope Inc. http://www.mellowhope.com. Slaivca's primary focus involves the enhancement and modification of existing approved drugs such as "Virazole" for the purpose of chemical repair of damage to the CNS (central nervous system), MS (Multiple Sclerosis), SARS, Hepatis C. Mellow Hope is China-based and is the biggest exporter of Biological Vaccines in China. It has a product line that encompasses vaccines for influenza, tetanus, diphtheria and other diseases; Blood based products including human rabies immunoglobulin; and active pharmaceutical ingredient (or APIs) for injection such as celestat in.
To receive future updates via email, including quarterly newsletters and company updates that may not be newsworthy, however important to the reader and followers of the company, please sign up today at http://www.minamargroup.com/updates.
most searched for:
http://www.boardcentral.com/boards/HTDS
MedClean Technologies (OTC: MCLN) Has Rare Opportunity to Emerge as Breakout Player in the Multi-Billion Dollar Regulated Medical Waste Market
http://studio-5.financialcontent.com/biomedreports/news/read?GUID=11030144
http://www.reportlinker.com/p0138412/Needle-Free-Injections-Clinical-Trial-Analysis.html
It is not possible to quote from this report because of law reasons. (THERE ARE MORE REPORTS ON BIOJECT INSULIN DELIVERY TESTING)
http://www.news-medical.net/news/20090911/Drug-manufacturers-are-seeking-out-needle-free-systems.aspx
I know that two of the biggest are testing now.
NEEDLE FREE MEANS NO ANTI BODY RESPONSE !!! THAT IS ONE OF THE BIGGEST SIDE EFFECTS OF NEEDLE INJECTION
Published papers which have compared the immunogenicity of Growth Hormone and Insulin when injected via needle and syringe or needle free methods have demonstrated no increase in immune response attributable to needle free injection. Indeed, antibody responses to insulin were less prevalent in subjects receiving needle free injection than in those employing needle and syringe.
IDC (Imaging Dynamics Company, Ltd.) is a medical technology company and innovative driving-force in the fast-growing field of digital radiography (DR) equipment.
IDC offers an extensive family of products, which can be found in many leading medical and healthcare facilities, in over 40 countries worldwide.
IDC’s X-Series product line is based on patented technology using a very high-density Charge Coupled Device (CCD) camera.
The Company's goal is to provide the highest image quality – at the lowest system cost. This approach has allowed IDC to successfully compete against other large manufacturers in the industry.
IDC tiered technology provides solutions for not only medical applications but additionally supports the orthopaedic, chiropractic and veterinary markets.
IDC was founded in May of 1995 and is publicly traded on the Toronto Stock Exchange (TSX) under the symbol IDL. Corporate headquarters are located in Calgary, Alberta, Canada.
http://www.imagingdynamics.com/images/pdfs/idc_dr_corp_brochure.pdf
Mr. Gruder could jeopardize our business operations and exhaust the Company’s cash reserve, which may result in investors losing their entire investment.
The Company has been responding to an investigation by the Securities and Exchange Commission (“SEC”), which commenced in December 2004. In connection with the investigation, the Company received a “Wells Notice” from the SEC indicating that the staff intends to recommend that the SEC institute an action against the Company, alleging that the Company violated Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder and Sections 5(a), 5(c), and 17(a) of the securities Act of 1933. The proposed allegations relate to purported representations that the Company made about one of the Company’s products regarding when the Company would be shipping the product, the product’s status with the Bureau of Alcohol, Tobacco, and Firearms, the performance of the product, and where the Company’s stock was trading. The allegations further related to the lack of registration for sales of stock in late 2004, made by three individuals who were not officers, directors, or employees of the Company. Under the Wells process established by the SEC, the Company has been provided an opportunity to respond in writing before the staff makes a formal recommendation to the SEC regarding any action. On May 1, 2008, the SEC announced that the Honorable Willis B. Hunt, United States District Judge for the Northern District of Georgia, entered a Final Judgment as to Defendant Stinger Systems, Inc. The Company was enjoined from future violations of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder. The Company consented to the entry of the final judgment without admitting or denying any of the allegations of the Commission’s Complaint. The Complaint, filed on January 28, 2008, alleged that from October 2004 through March 2005, the Company and its president, Robert F. Gruder, made a series of fraudulent material misrepresentations and omissions regarding the Company’s “flagship” stun gun product. According to the Complaint, the misrepresentations consisted of press releases and direct mailings to thousands of law enforcement officers and agencies, suggesting that Stinger was manufacturing, selling and shipping its stun gun. In fact, the product was still in the development phase. The Complaint further alleged that the misrepresentations consisted of statements on the Company’s website and/or in industry publications that indicated the Company’s stock was trading on NASDAQ, when in fact it was not. The Complaint also alleged that the Company and Mr. Gruder misrepresented that the Bureau of Alcohol, Tobacco and Firearms (“ATF”) certified the Company’s stun gun, even though the ATF offered no such certification. According to the Complaint, these misrepresentations caused a spike in the trading volume and price for the Company’s shares once it began publicly trading in November 2004. The charges in the Complaint against Mr. Gruder have not been settled and a judgment adverse to Mr. Gruder could jeopardize our business operations and exhaust the Company’s cash reserve, which may result in investors losing their entire investment.
BIOMEDREPORTS HAS SOME GOOD INSIDE INFORMATION ON MCLN
Needle free means also no antibody response !! Anti body response is one one of the dangers in insulin WITH needle. Bioject with a NEEDLE-FREE injection doesn't have this severe side effect. THIS IS A GREAT ADVANTAGE
Published papers which have compared the immunogenicity of Growth Hormone and Insulin when injected via needle and syringe or needle free methods have demonstrated no increase in immune response attributable to needle free injection. Indeed, antibody responses to insulin were less prevalent in subjects receiving needle free injection than in those employing needle and syringe.
Bioject the first needle free insulin treatment for one of the biggest insulin pharmaceutical company will be a fact in the near future.
Bioject Medical Technologies wants to give the medical community a shot in the arm. Its needle-free injection system delivers injectable medication without a needle (and thus without needle-associated risks) by using a fine, high-pressure stream that goes through the skin; the injector is powered by CO2 disposable cartridges or tanks. The accompanying vial adapter device allows the Biojector system to be filled without a needle. The company also markets Vitajet, a spring-powered, needle-free self-injection device that has been cleared for administering injections of insulin and Merck Serono's human growth hormones. Investment firm Signet Healthcare Partners and affiliates own one-third of Bioject.
Biojector 2000
Cool.clickTM
SeroJetTM
Drug Reconstitution System
Needle-Free Vial Adapter
Their latest big hit Firefighter is rated "E" 10+ which includes almost everyone. More parents will likely buy this game over the violent ones for their kids.
"The launch of `Real Heroes: Firefighter` has exceeded our expectations and we expect to see continued demand for the game into the holiday season," commented Sirus Ahmadi, CEO of Conspiracy Entertainment. "Our first project with Epicenter Studios could not have turned out any better and we look forward to building upon this relationship with future projects."
Over the last eighteen (18) months, the Company has been hard at work developing a portfolio of titles for 2008/2009; releasing fourteen (14) titles on most major game platforms and personal computers.
Conspiracy Entertainment published in August its “Real Heroes: Firefighter” game for Wii™, the first Conspiracy financed development title in many years. Developed by Epicenter Studios, "Real Heroes: Firefighter" emphasizes non-violent, game-integral puzzles and challenges that mirror the on-the-fly choices firefighters face every day. The Company is pleased with its launch and expects to see continued demand for the game into the holiday season as well as opportunities for future projects with Epicenter Studios.
Estimated intermediate target price at $.43.
Authorized shares is not the same as outstanding shares !
Outstanding Shares
Not to be confused with authorized shares, outstanding shares refer to the number of stocks that a company actually has issued. This number represents all the shares that can be bought and sold by the public as well as all the restricted shares that require special permission before being transacted. As we already explained, shares that can be freely bought and sold by public investors are called the float, and this value changes depending on if the company wishes to repurchase shares from the market or sell out more of its authorized shares within its treasury.
sec is clear
company mail
Stockholders’ Deficit:
Common Stock
Authorized 1,700,000,000 Shares, par value .001 per
Share Issued Shares, 1,689,092,864 - Outstanding
Shares, 1,687,592,864
Tune in for legal action against a moderator and a poster
SMJJ be afraid of legal action Your posting as a moderator of the outstanding shares is NOT correct.
pinksheets.com:
Estimated Market Cap
$304,541 as of Sep 11, 2009
Outstanding Shares
1,522,703,975 as of Mar 3, 2009
Authorized Shares
1,700,000,000 as of Mar 9, 2009
Number of Share Holders of Record
88 as of Nov 17, 2008
OUTSTANDING SHARES WELLSTAR INT.
10-Q
Stockholders’ Deficit:
Common Stock
Authorized 1,700,000,000 Shares, par value .001 per
Share Issued Shares, 1,689,092,864 - Outstanding
Shares, 1,687,592,864 (4/30/09) and 460,040,217 (7/31/08)
NOVADEL's SUMATRIPTAN SPRAY works faster in a lower dose than
50-mg TABLET
http://www.novadel.com/pipeline/index.htm
TWO PRODUCTS ALREADY FDA APPROVED
The role of liver stem cells in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma in humans arises by maturation arrest of liver stem cells. "MultiCell intends to use its human liver cell and liver stem cell assets to identify therapeutic targets and new drug candidates specifically targeting the treatment of primary liver cancer and intrahepatic bile duct cancer," said Jerry Newmin, Chairman & CEO of MultiCell Technologies. "We believe our engineered human liver cell lines will play an important role as proxies for normal human liver cells in our effort to identify drug targets."
MultiCell also owns exclusive worldwide rights to two issued U.S. patents (6,872,389 and 6,129,911), one U.S. patent application (U.S. 2006/0019387A1), and several corresponding issued and pending foreign patents and patent applications related to the isolation and differentiation of human liver stem cells. MultiCell previously announced it had entered into a cooperative research and development agreement with Maxim Biotech, Inc. to develop products for the study of human liver stem cells and human liver cancer.
Why So highly undervalued ?
Estimated Market Cap
$2,078,497 as of Aug 21, 2009
Outstanding Shares
69,283,249 as of Jul 14, 2008
MultiCell has licensed several pharmaceutical companies rights to use the Fa2N-4 cell line for drug toxicity applications including Pfizer, Bristol-Myers Squibb, and Eisai Pharmaceuticals. MultiCell licensed Corning, Inc. to sell the Fa2N-4 cell line and media within the drug discovery and life science research markets for drug toxicity (Tox) applications as well as for drug adsorption, distribution, metabolism and excretion (ADME) studies.
AETHLON maker of the next hemodiafiltration (HDF) similar to nephros.
CASHBURN DILUTION
As of June 30, 2009, we require approximately $175,000 per month to fund our operations. This amount may increase as we expand our sales and marketing efforts and develop new products and services; however, if we do not raise additional capital in the near future we will have to curtail our spending and downsize our operations. Our cash needs are primarily attributable to funding sales and marketing efforts, strengthening our training capabilities, satisfying existing obligations and building an administrative infrastructure, including costs and professional fees associated with being a public company.
We are currently seeking up to $5 million in capital through a private placement of our common stock. The exact amount of funds raised, if any, will determine how aggressively we can grow and what additional projects we will be able to undertake. No assurance can be given that we will be able to raise additional capital, when needed or at all, or that such capital, if available, will be on terms acceptable to us. If we are unable to raise additional capital in the current private offering, we could be required to substantially reduce operations, terminate certain products or services or pursue exit strategies.
To support ongoing operations while seeking the above mentioned $5 million dollar capital raise the Company has also initiated a $500,000 convertible bridge loan agreement as identified in our Current Report on Form 8-K filed with the SEC on July 15, 2009. The Company engaged Hallmark Investments, Inc. (“Hallmark”) to act as its placement agent on an exclusive basis in connection with this private placement. The Company expects this financing will meet its short term cash requirements while securing its larger private placement.
Our registered independent certified public accountants have stated in their report dated April 15, 2009, filed with the Company’s Annual report on form 10-K that the Company has a generated negative cash outflows from operating activities, experienced recurring net operating losses, and is dependent on securing additional equity and debt financing to support its business efforts. These factors among others may raise substantial doubt about our ability to continue as a going concern.
ISR: FDA Expanded Clearance for Proxcelan(TM) Cesium-131 Brachytherapy Seeds
Why Cephalon sell rights to acusphere ?????????/
IsoRay Announces First Head And Neck Cancer Treated With Cesium-131
Richland, WA (July 28, 2009) — IsoRay, Inc. (Amex: ISR) announced today that on June 4, 2009, Dr. Karen Pitman of the Department of Otolaryngology and Communicative Sciences and Dr. Michael Baird of the Radiation Oncology Department of the University of Mississippi Medical Center performed the world’s first head and neck permanent seed Cesium-131 implant.
The implant was performed using Vicryl- embedded seeds in the tonsilar area in a patient who had locally failed IMRT external beam radiation and chemotherapy. Drs. Pitman and Baird chose Cesium 131 for this implant based on its high energy (30.4 kev) and short half-life (9.7 days). This combination allowed them to achieve a high dose of radiation to the recurrent disease, while limiting the dose to the previously heavily irradiated tissues of the neck. Cesium’s short half-life reduced the duration of side effects and the need for radiation protection.
Dr. Baird stated, “Although too early to determine the overall efficacy of treatment, the patient’s tolerance to the implant has been good. His acute reactions peaked at three weeks, and have resolved by six weeks. His clinical reaction in the implant volume corresponds well to the post implant dosimetry.”
Until now clinical experience with Cesium-131 has been focused on prostate cancer and ocular melanoma. However, Cesium-131 has been cleared by the FDA for use in the treatment of malignant disease (e.g., prostate, ocular melanoma, head and neck, lung, brain, breast, etc.) and may be used in surface, interstitial, and intracavitary applications for tumors with known radiosensitivity.
Dwight Babcock, IsoRay's CEO, stated “This is an important development in our strategy to significantly broaden our base beyond prostate cancer. Cesium-131 has unique characteristics for treating many additional cancers such as this new application that provided a minimally invasive treatment option for this patient.”
About IsoRay
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of the Proxcelan Cesium-131 brachytherapy seeds, used to treat prostate, ocular melanomas, and other cancers. Proxcelan seeds offer a significantly shorter half-life than the two other isotopes commonly used for brachytherapy, which results in a substantially faster delivery of therapeutic radiation, lower probability of cancer cell survival and reduction of the longevity of common brachytherapy side effects. (a) (b). IsoRay is based in Richland, Washington. More information is available about IsoRay at www.isoray.com.
(a) Armpilia CI, Dale RG, Coles IP, et al. The Determination of Radiobiologically Optimized Half-lives for Radionuclides Used in Permanent Brachytherapy Implants. Int. J. Radiation Oncology Biol. Phys. 2003; 55 (2): 378-385.
(b) Prestidge B.R., Bice W.S., Jurkovic I., et al. Cesium-131 Permanent Prostate Brachytherapy: An Initial Report. Int. J. Radiation Oncology Biol. Phys. 2005; 63 (1): 5336-5337.
price polysilicon down
Polysilicon is supplied to both the solar and electronics
industries which currently are operating below capacity, giving rise to significantly increased supply of
polysilicon leading to a decline in the spot price of polysilicon from highs of $400 per kg at its peak in
2008 to a range of $100-150 per kg in the first quarter 2009.
inTEST Reports Second Quarter 2009 Results
Press Release
Source: inTEST Corporation
On Wednesday August 5, 2009, 4:00 pm EDT
Buzzed! 1 Print.Companies:InTEST Corp.
CHERRY HILL, N.J., Aug. 5 /PRNewswire-FirstCall/ -- inTEST Corporation (Nasdaq: INTT - News), an independent designer, manufacturer and marketer of semiconductor automatic test equipment (ATE) interface solutions and temperature management products, today announced results for the quarter and six months ended June 30, 2009.
Net revenues for the quarter ended June 30, 2009 were $4.7 million, compared to $4.4 million for the first quarter of 2009. Our net loss for the second quarter of 2009 was $(2.0) million or $(0.20) per diluted share, compared to a net loss of $(2.8) million or $(0.28) per diluted share for the first quarter of 2009. The net loss for the second quarter of 2009 included restructuring charges of $(269,000) or $(0.03) per diluted share. The net loss for the first quarter of 2009 included restructuring charges of $(60,000) or $(0.01) per diluted share. The restructuring charges recorded during the second quarter of 2009 were incurred by all of our product segments, while the restructuring charges recorded during the first quarter were incurred by our Thermal Products segment only. The restructuring charges consist of one-time termination benefits as a result of our recent workforce reductions in these segments.
Robert E. Matthiessen, President and Chief Executive Officer of inTEST commented, "This has been the deepest downturn in the history of our industry; however, we believe we may have seen the bottom of the cycle during the quarter ended June 30, 2009. It has been our experience in the past that our docking hardware business leads us out of down-cycles and we have seen a significant increase in this part of our business during the second quarter of 2009. While consolidated bookings increased 21% in the second quarter of 2009 to $4.6 million from the first quarter bookings of $3.8 million, our Mechanical Product segment's second quarter bookings (which include both docking hardware and manipulators) increased 90% over the first quarter of 2009 from $1.1 million to $2.0 million, with the majority of this increase in docking hardware bookings. Our Thermal Product segment's business has not yet shown a turnaround, as second quarter bookings for this segment declined 9% from the level achieved during the first quarter of 2009. Historically, we have found that the Thermal Product segment's semiconductor demand normally trails that of our other two product segments by a quarter or two and we would therefore expect improvements in that business nearer the end of the fiscal year. "
Conference Call Information
There will be a conference call with investors and analysts this evening at 5:00 pm ET to discuss the Company's second quarter 2009 results and management's current expectations and views of the industry. The call may also include discussion of strategic, operating, product initiatives or developments, or other matters relating to the Company's current or future performance.
About inTEST Corporation
inTEST Corporation is an independent designer, manufacturer and marketer of ATE interface solutions and temperature management products, which are used by semiconductor manufacturers to perform final testing of integrated circuits (ICs) and wafers. The Company's high-performance products are designed to enable semiconductor manufacturers to improve the speed, reliability, efficiency and profitability of IC test processes. Specific products include positioner and docking hardware products, temperature management systems and customized interface solutions. The Company has established strong relationships with semiconductor manufacturers globally, which it supports through a network of local offices. For more information visit www.intest.com.
The three-month period ended March 31, 2009 as compared to the three months ended March 31, 2008
For the three months ended March 31, 2009, revenues increased by $564,456 or 20.4% to $3,329,952 from $2,765,496 in the corresponding period of the prior year. The increase in revenues was attributable to the fact that the Company is continuing to expand its productions and distribution, and its products are better accepted by the Chinese market customers. These products include Cactus Protein Nutrient, Cactus Calcium Peptide Soft Capsule and Cactus Shuxin Capsule, among others. In addition, the Company successfully launched two new products, cactus fish feed and cattle feed, in July 2008, which also contributed to the increase in sales
China Organic Agriculture Announces First Quarter 2009 Financial Results
Company Reports $36.7 Million Revenue, $3.9 Million Net Income and EPS of $0.05 for Q1 2009
China Kangtai Cactus Biotech Inc. to Launch Patented Cactus Hog Feed.
The company plans to begin marketing cactus hog feed in the forth quarter in 2009, following the successful launch of cactus cattle feed and fish feed in July 2008. The new patented hog feed is expected to increase 2009 sales by approximately $330,000.
China Architectural Engineering Announces New Contract to Build Resort Near Shanghai
China Architectural Engineering, Inc. (NASDAQ: CAEI - News), which began operations in 1992, has maintained a leading position in the global commercial construction industry by providing timely, high-quality, reliable, fully integrated and cost-effective service solutions to our clients utilizing specialized technical expertise in the design, engineering, fabrication and construction of structural exterior cladding systems. It specializes in high-end curtain wall systems (including glass, stone and metal curtain walls), roofing systems, steel construction systems, eco-energy saving building conservation systems and related products, for public works and commercial real estate projects.
CAEI has worked with world-renowned architects and building engineers from China and other countries and has completed over one-hundred large, complex and unique projects throughout China, Hong Kong, Macau, Australia and Southeast Asia, including numerous award-winning landmark buildings in many of Asia’s major cities. CAE has also expanded beyond China into some of the growing construction markets in the world, such as Middle East, Central Asia and Eastern Europe.
I Think it will fall back when missing uptrend this week
Featured US Exporters Listing in QatarR
http://www.buyusa.gov/qatar/en/70.html?exp_cat=6010&exp_pid=116
July 15, 2009,Universal Detection Technology's Handheld Biodetection Kits Receive Department of Homeland Security SAFETY Act Certification.
Kits Detect Anthrax, Ricin, and Other Bio-Agents
SAFETY Act provides incentives for the development and deployment of anti-terrorism technologies by creating a system of "risk management" and a system of "litigation management." The purpose of the Act is to ensure that the threat of liability does not deter potential manufacturers or Sellers of anti-terrorism technologies from developing and commercializing technologies that could save lives. The Act creates certain liability limitations for "claims arising out of, relating to, or resulting from an act of terrorism" where qualified anti-terrorism technologies have been deployed.
The handheld detection kits have been extensively used by first responders and private industry throughout the country. The equipment has been evaluated by the U.S. DOD as well as the United Kingdom military. The equipment's capacities include:
�
-- No cross-reactivity with near neighbor strains
-- No cross-reactivity to household powders
-- No set up time
-- No expensive reader needed
-- No decontamination requirements
-- No false positives
-- No false negatives
-- No hook effect
Department of Homeland Security Certifies Universal Detection Technology's Handheld Biodetection Kits for Counter-Terrorism
Dr. Geoffrey O'Neill received his Ph.D. in Immunology from the University of Glasgow in 1973. In 1974, he undertook post-doctoral training under the guidance of Dr. Robert A. Good (who performed the first bone marrow transplantation in a patient with immunodeficiency) at Memorial Sloan-Kettering Cancer Center in New York. Dr. O'Neill's field of study at Sloan-Kettering was transplantation immunobiology.
Dr. O'Neill brings over twenty five years experience as a visionary and pioneer in his field, achieving recognition from his colleagues as the recipient of the Jean Julliard Prize for Outstanding Research from the International Society of Blood Transfusion and International Society of Hematology, presented in Budapest, Hungary. He also received the JM Foundation Award, New York, for innovative research.
Dr. O'Neill's academic career covers tenures such as Visiting Professor, NIH-RCMI Program, University of Puerto Rico, School of Medicine, San Juan; Associate Professor of Pathology and Assistant Medical Director, Transfusion Medicine, University of Miami, Jackson Memorial Hospital; Visiting Professor, Institute of Immunology, University of Munich, FRG; and Associate Professor of Graduate Medical Sciences, Cornell University School of Medicine New York.
Having authored and co-authored over 90 publications gsk in the field of bone marrow transplantation and stem cell biology, Dr. O'Neill brings to the company entrepreneurial and leadership skills necessary to explore and pioneer new technologies and innovative therapies. Complementing his extensive research activities and academic achievements, Dr. O'Neill also brings strong practical implementation skills to Bio-Matrix Scientific Group Inc., having held numerous directorships.
THE SECRET INVESTOR IS ON OF THE BIGGEST AMERICAN PHARMACEUTICAL COMPANIES